Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma [Research Watch]

Axitinib plus pembrolizumab has a 73% response rate in previously untreated advanced renal cell carcinoma.

from Cancer via ola Kala on Inoreader http://ift.tt/2BMpMCo
via IFTTT